Tecentriq 840 mg concentrate for solution for infusion
- Name:
Tecentriq 840 mg concentrate for solution for infusion
- Company:
Roche Registration GmbH
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 27/03/20
(Click to Download)Click on this link to Download PDF directly
Roche Registration GmbH
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 27 March 2020 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 27 March 2020 PIL
Reasons for updating
- Change to section 2 - use in children and adolescents
Updated on 4 March 2020 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 4 March 2020 PIL
Reasons for updating
- Change to Section 1 - what the product is
- Change to section 1 - what the product is used for
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 24 February 2020 SmPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 24 February 2020 PIL
Reasons for updating
- Change to section 6 - what the product contains
- Change to section 6 - date of revision
Updated on 12 September 2019 PIL
Reasons for updating
- Change to section 4 - possible side effects
Updated on 12 September 2019 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
EMEA/H/C/004143/II/0018 , CDS Update - Non Safety, 12.0, Variation type II too seek approval for: Extension of the use of Tecentriq (atezolizumab) in combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). EMEA/H/C/004143/II/0019, CDS Update - Non Safety, 13.0, The changes relate to the results from study IMPower130 supporting extension of indication to: Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC. Existing text in SmPC (sections 4.1, 4.2, 4.8 and 5.1) has been updated to include results from the above study.
Updated on 12 September 2019 PIL
Reasons for updating
- Change to section 4 - possible side effects
Updated on 4 September 2019 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 4 September 2019 PIL
Reasons for updating
- New PIL for new product